Menu Search
Equities

S2Medical AB (publ)

  • Add to watchlist
  • Add to portfolio
  • Add an alert
S21:FRA

S2Medical AB (publ)

Actions
  • Price (EUR)0.0002
  • Today's Change0.00 / 0.00%
  • Shares traded46.50k
  • 1 Year change-75.00%
  • Beta2.8404
Data delayed at least 15 minutes, as of Feb 16 2026 07:09 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

S2Medical AB (publ) is a Sweden-based medical technology company. The Company focuses on developing products for healing burns and chronic wounds, from debridement and granulation to reepithelialization. The Company's product portfolio includes INSTAQRETT, a sterile single-use mechanical debridement tool, the Epiprotect product line based on its collagen-mimicking Eiratex material, which includes EPIPROTECT Safestop, a blood-stilling membrane dressing, EPIPROTECT 2117, a synthetic substitute to allografts and xenografts, EPIPROTECT ULCER, dressing for treating ulcers, as well as INSTABIND bandages and Instagraft, a single-use medical device designed to treat chronic wounds with microtransplants from the patient's own skin without creating any new wounds. The Company is also the official distributor of Silverlon antimicrobial dressings for Nordic countries. In addition, it operates the S2Clinic, a wound healing center in Sweden.

  • Revenue in SEK (TTM)18.87m
  • Net income in SEK-996.45k
  • Incorporated2013
  • Employees17.00
  • Location
    S2Medical AB (publ)Sunnorpsgatan 5LINKOPING 582 73SwedenSWE
  • Phone+46 87000050
  • Websitehttps://www.s2m.se/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.